期刊文献+

HPLC测定人血浆乙酰水杨酸酯酶活性及其测定培养条件的优化选择 被引量:8

Determination of the Activity of Aspirin Esterase in Plasma by HPLC Method and Optimization of the Incubated Conditions in Vitro
下载PDF
导出
摘要 目的建立测定血浆中乙酰水杨酸和水杨酸浓度的高效液相色谱法,采用水杨酸/(乙酰水杨酸+水杨酸)表示乙酰水杨酸酯酶的活性,并对乙酰水杨酸酯酶体外培养条件进行了优化,测定血浆乙酰水杨酸酯酶活性可为临床合理用药提供科学依据。方法采用反相高效液相直接进样法测定血浆中乙酰水杨酸和水杨酸的浓度,并用正交实验设计分析法对其体外培养条件进行优化选择。结果乙酰水杨酸在0.08-5.12mg·L^-1内线性关系良好,水杨酸在0.05-4mg·L^-1内线性关系良好,体外最佳培养条件是A2B2C3D1,即以1mmol·L^-1乙酰水杨酸,200μL血浆,在pH为7.6的培养液中培养20min。结论本法操作简便、灵敏、快速,适用于血浆中乙酰水杨酸和水杨酸的浓度测定。 OBJECTIVE To develop a HPLC method for the determination of aspirin and salicylic acid in plasma, and use the ratio of salicylic acid/( aspirin + salicylic acid)to express the activity of aspirin esterase, and optimize the incubated conditions of aspirin esterase. METHODS The contents of aspirin and salicylic acid in the plasma were determined by RP-HPLC method. Orthogonal experimental design was used to optimize the incubated conditions of aspirin esterase. RESULTS Calibration curves of aspirin were linear in the range of 0. 08 - 5. 12 mg·L^-1( r = 0. 999 5 ). Calibration curves of salicylic acid were linear in the range of 0. 05 - 4 mg·L^-1 ( r = 0. 999 8 ). The optimal incubated conditions were abtained that 1 mmol ·L^-1 aspirin and 200 μL plasma were incubated for 20 min in pH 7.6 incubation buffer. CONCLUSION The method is simple, accurate and rapid, suitable for the determination of aspirin and salicylic acid in plasma. The method can be used to assay the activities of aspirin esterase.
出处 《中国药学杂志》 CAS CSCD 北大核心 2007年第11期849-852,共4页 Chinese Pharmaceutical Journal
关键词 血浆乙酰水杨酸酯酶活性 高效液相色谱法 正交实验设计 优化 the activity of aspirin esterase HPLC orthogonal experimental design optimization
  • 相关文献

参考文献3

  • 1王世雄,陈世民.阿斯匹林的药理学研究进展[J].海南医学院学报,2001,7(1):61-64. 被引量:17
  • 2ABOU-HATAB K,SINEAD O MAHONY M,PATEL S,et al.Relationship between age and plasma esterases[J].Age Aging,2001,30:41-45.
  • 3BENEDITO MAC.Fluorimetric determination of tissue distribution and differences between the activity of aspirin esterases Ⅰ and Ⅱ in mice and rats[J].J Pharm Pharmacol,997,49:273-276.

二级参考文献31

共引文献16

同被引文献40

  • 1杜冠华,裘月,张均田.丹酚酸A对大鼠心肌缺血再灌注性损伤的保护作用[J].药学学报,1995,30(10):731-735. 被引量:53
  • 2常明,王晓燕,赵洁生,张相林.人血浆中佐匹克隆的测定及药动学研究[J].中国临床药学杂志,2005,14(5):285-288. 被引量:4
  • 3司天梅,舒良,张鸿燕,孙丽丽.佐匹克隆片在健康志愿者体内的生物等效性[J].中国临床药理学杂志,2006,22(3):202-205. 被引量:3
  • 4李彬,毛静远,王强,张运,张其梅,郑颖.三七总苷对阿司匹林抵抗影响的临床观察[J].中西医结合心脑血管病杂志,2007,5(7):579-581. 被引量:18
  • 5中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组.中国缺血性脑卒中和短暂性脑缺血发作二级预防指南[J].中华神经科杂志,2010,43:154-160.
  • 6Antithrombotic Trialists ' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ, 2002,324 : 71-86.
  • 7Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol,2001,88(3) :230-235.
  • 8Abou-Hatab K, O'Mahony M S, Patel S, Woodhouse K. Relationship between age and plasma esterases [J]. Age and Aging, 2001,30 ( 1 ) : 41-45.
  • 9Zhou L,Zuo Z,Chow MS.Danshen:an overview of its chemistry,pharmacology,pharmcokinetics,and clinical use[J].J Clin Pharmacol,2005;45:1345-1359.
  • 10Izzo AA,Di Carlo G,Borrelli F,et al.Cardiovascular pharmacotherapy and herbal medicines:the risk of drug interaction[J].Int J Cardiol,2006;98:1-14.

引证文献8

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部